These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 16258527)

  • 21. JNJ-10280205 and JNJ-10287069: Novel PDE5 inhibitors as clinical candidates for erectile dysfunction.
    Qiu Y; Bhattacharjee S; Kraft P; Mathew John T; Haynes-Johnson D; Jiang W; Sui Z; Lundeen S
    Int J Impot Res; 2006; 18(5):477-83. PubMed ID: 16528290
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular modeling studies of pyridopurinone derivatives--potential phosphodiesterase 5 inhibitors.
    Srivani P; Srinivas E; Raghu R; Sastry GN
    J Mol Graph Model; 2007 Jul; 26(1):378-90. PubMed ID: 17307372
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A 46-amino acid segment in phosphodiesterase-5 GAF-B domain provides for high vardenafil potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerization.
    Blount MA; Zoraghi R; Ke H; Bessay EP; Corbin JD; Francis SH
    Mol Pharmacol; 2006 Nov; 70(5):1822-31. PubMed ID: 16926278
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PDE5 inhibitors: is there more to come besides erectile dysfunction?
    Stief C
    Eur Urol; 2007 Oct; 52(4):943-4. PubMed ID: 17683851
    [No Abstract]   [Full Text] [Related]  

  • 25. 3D-QSAR studies on sildenafil analogues, selective phosphodiesterase 5 inhibitors.
    Yoo J; Thai KM; Kim DK; Lee JY; Park HJ
    Bioorg Med Chem Lett; 2007 Aug; 17(15):4271-4. PubMed ID: 17553682
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gene therapy and erectile dysfunction: the current status.
    Lau DH; Kommu SS; Siddiqui EJ; Thompson CS; Morgan RJ; Mikhailidis DP; Mumtaz FH
    Asian J Androl; 2007 Jan; 9(1):8-15. PubMed ID: 16888683
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Time-dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4 and 5 inhibitors.
    Rutten K; Prickaerts J; Hendrix M; van der Staay FJ; Sik A; Blokland A
    Eur J Pharmacol; 2007 Mar; 558(1-3):107-12. PubMed ID: 17207788
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High lung PDE5: a strong basis for treating pulmonary hypertension with PDE5 inhibitors.
    Corbin JD; Beasley A; Blount MA; Francis SH
    Biochem Biophys Res Commun; 2005 Sep; 334(3):930-8. PubMed ID: 16023993
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potent and selective xanthine-based inhibitors of phosphodiesterase 5.
    Arnold NJ; Arnold R; Beer D; Bhalay G; Collingwood SP; Craig S; Devereux N; Dodds M; Dunstan AR; Fairhurst RA; Farr D; Fullerton JD; Glen A; Gomez S; Haberthuer S; Hatto JD; Howes C; Jones D; Keller TH; Leuenberger B; Moser HE; Muller I; Naef R; Nicklin PA; Sandham DA; Turner KL; Tweed MF; Watson SJ; Zurini M
    Bioorg Med Chem Lett; 2007 Apr; 17(8):2376-9. PubMed ID: 17337182
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 1: 5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6]pyrido[3,4-b]indole-1,3(2H)-dione analogues.
    Daugan A; Grondin P; Ruault C; Le Monnier de Gouville AC; Coste H; Kirilovsky J; Hyafil F; Labaudinière R
    J Med Chem; 2003 Oct; 46(21):4525-32. PubMed ID: 14521414
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Udenafil, a long-acting PDE5 inhibitor for erectile dysfunction.
    Salem EA; Kendirci M; Hellstrom WJ
    Curr Opin Investig Drugs; 2006 Jul; 7(7):661-9. PubMed ID: 16869121
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PDE5 inhibitors and permanent visual loss.
    Tomsak R
    Int J Impot Res; 2005; 17(6):547-9. PubMed ID: 16193072
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phosphodiesterase type 5 inhibitors' extended duration of response as a variable in the treatment of erectile dysfunction.
    Dunn ME; Althof SE; Perelman MA
    Int J Impot Res; 2007; 19(2):119-23. PubMed ID: 16738695
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PDE5 inhibitors: are there differences?
    Carson CC
    Can J Urol; 2006 Feb; 13 Suppl 1():34-9. PubMed ID: 16526979
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Review of time of onset and duration of clinical efficacy of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction.
    Shabsigh R; Seftel AD; Rosen RC; Porst H; Ahuja S; Deeley MC; Garcia CS; Giuliano F
    Urology; 2006 Oct; 68(4):689-96. PubMed ID: 17070333
    [No Abstract]   [Full Text] [Related]  

  • 36. Recent insights into androgen action on the anatomical and physiological substrate of penile erection.
    Gooren LJ; Saad F
    Asian J Androl; 2006 Jan; 8(1):3-9. PubMed ID: 16372114
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low-dose phosphodiesterase inhibition improves responsiveness to inhaled nitric oxide in isolated lungs from endotoxemic rats.
    Klein A; Zils U; Bopp C; Gries A; Martin E; Gust R
    J Surg Res; 2007 Apr; 138(2):224-30. PubMed ID: 17275845
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism.
    Burnett AL; Bivalacqua TJ; Champion HC; Musicki B
    Urology; 2006 May; 67(5):1043-8. PubMed ID: 16698365
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Treatment of pulmonary arterial hypertension: phosphodiesterase-5 inhibitors].
    Ghofrani HA; Grimminger F
    Dtsch Med Wochenschr; 2006 Dec; 131(49 Suppl 9):S311-4. PubMed ID: 17139594
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term continuous treatment with sildenafil ameliorates aging-related erectile dysfunction and the underlying corporal fibrosis in the rat.
    Ferrini MG; Kovanecz I; Sanchez S; Vernet D; Davila HH; Rajfer J; Gonzalez-Cadavid NF
    Biol Reprod; 2007 May; 76(5):915-23. PubMed ID: 17287493
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.